Bottomline: InvAscent-backed Symbiotec has struggled to break out; will FY25 be different?

Premium

Homegrown corticosteroid and hormones API-maker Symbiotec Lifesciences Pvt. Ltd’s revenue and profitability took a hit in FY23, even as the outlook for this financial year and the next (FY25) remains promising, VCCircle has learnt.  The company was bogged down by multiple factors like capital expenditure for greenfield projects, volatile pricing of ......